Soy Protective Against Localized Prostate Cancer, But Not Advanced Prostate Cancer
Apr-04-2007
The largest study examining the relationship between the traditional soy-rich Japanese diet and development of prostate cancer in Japanese men has come to a seemingly contradictory conclusion: intake of isoflavone chemicals, derived largely from soy foods, decreased the risk of localized prostate cancer but increased the risk of advanced prostate cancer. The prospective study of 43,509 men, published in the March issue of Cancer Epidemiology, Biomarkers & Prevention, suggests that the effects of isoflavones on prostate cancer development may differ according to disease stage, say researchers at the National Cancer Center in Japan. One possible explanation is that isoflavones may delay the progression of latent prostate cancer only; on...
Research From The United States And Canada Yields New Prostate Cancer Findings
Apr-04-2007
Prostate cancer is the focus of recent research from the United States and Canada. Study 1: Researchers detail in "High bone density is associated with prostate cancer in older Afro-Caribbean men: Tobago prostate survey," new data in prostate cancer. In this recently published article, scientists in the United States conducted a study "To test the hypothesis that bone mineral density (BMD), a possible surrogate of lifetime exposure to hormone/growth factor/vitamin D/calcium exposure, is higher in prostate cancer cases than controls. Hip BMD was measured by dual X-ray absorptiometry in 222 Afro-Caribbean screening-detected prostate cancer cases and 1,503 screened non-cases, aged 45-79, in the population-based Tobago Prostate Survey." "...
PSA May Be Poor Predictor of Lethal Prostate Cancer
Apr-04-2007
Title: PSA May Be Poor Predictor of Lethal Prostate Cancer
Category: Health News
Created: 4/5/2007 2:00:00 AM
Last Editorial Review: 4/5/2007
Category: Health News
Created: 4/5/2007 2:00:00 AM
Last Editorial Review: 4/5/2007
Hormone Therapy for Advanced Prostate Cancer Not for Everyone
Apr-02-2007
Title: Hormone Therapy for Advanced Prostate Cancer Not for Everyone
Category: Health News
Created: 4/3/2007 2:00:00 AM
Last Editorial Review: 4/3/2007
Category: Health News
Created: 4/3/2007 2:00:00 AM
Last Editorial Review: 4/3/2007
New Study May Help Doctors Select Prostate Cancer Treatments
Apr-06-2007
The work comparing interstitial brachytherapy and radical prostatectomy for low-risk localized prostate cancer shows that the 2 treatments share a similar cost profile, but have varying side effects and a different impact on quality of life.
Medscape Medical News
Allison Gandey
Medscape Medical News
Allison Gandey
Cleveland will test new prostate cancer drug
Apr-05-2007
Cleveland BioLabs has said it intends to begin a phase II efficacy study for Curaxin CBLC102 in advanced, hormone-refractory prostate cancer after the criterion for initiation was met.
2 Rutgers College Of Nursing Professors Study Patients With Prostate Cancer
Apr-04-2007
Main Category: Prostate / News Article Date: 04 Apr 2007 - 17:00 PDT Two Rutgers College of faculty members are conducting a study to develop and test a targeted intervention to reduce ...
Cleveland BioLabs Phase II Hormone-Refractory Prostate Cancer Trial Advances to Next Phase
Apr-06-2007
Cleveland BioLabs, Inc. , announced today that its Phase II efficacy study for Curaxin CBLC102 in advanced, hormone-refractory has progressed to the next phase.